Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
70 hedge funds and large institutions have $313M invested in Aptose Biosciences, Inc. in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 11 closing their positions.
96% more call options, than puts
Call options by funds: $2.69M | Put options by funds: $1.37M
47% more capital invested
Capital invested by funds: $214M → $313M (+$99.4M)
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
22% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 18
8% more funds holding
Funds holding: 65 → 70 (+5)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$17.6M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$9.97M |
| 3 |
VA
VR Adviser
New York
|
+$7.07M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$5.54M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$2.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$12.7M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$5.45M |
| 3 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$3.97M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$2.97M |
| 5 |
6CM
683 Capital Management
New York
|
-$2.49M |
APTO Hedge Fund Activity: Q1 2021 in Review
70 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q1 2021, worth a combined $313M — up 47% from $214M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new APTO positions and 11 closed out — a net gain of 5 holders — while 22 added to existing stakes and 18 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $17.6M. The largest seller was Corriente Advisors, exiting entirely with an estimated $12.7M sold.
- 70 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q1 2021, up from 65 in Q4 2020.
- Funds reported $313M of Aptose Biosciences, Inc. stock for Q1 2021, up 47% quarter-over-quarter.
- 16 funds opened new Aptose Biosciences, Inc. positions in Q1 2021 and 11 closed out, a net change of +5 holders.
- The largest Aptose Biosciences, Inc. buyer in Q1 2021 was Cormorant Asset Management, an estimated $17.6M added.
- The largest Aptose Biosciences, Inc. seller in Q1 2021 was Corriente Advisors, an estimated $12.7M sold.
Based on aggregated 13F filings for Q1 2021.